Menlo’s solo pipeline drug suffers another ugly trial failure, done in by an outperforming placebo
Six months ago Menlo Therapeutics $MNLO saw its newly-public shares implode on a Phase II failure for its sole drug in pruritus. Today, the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
